Radiochemotherapy of hepatocarcinoma via lentivirus-mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene

Nuclear Medicine and Biology

Volumn 38, Issue 5, 2011, Pages 757-763

  Chen, Libo ^a   Guo, Guoying ^b   Liu, Tianjing ^c   Guo, Lihe ^c   Zhu, Ruisen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Gene therapy; Hepatocarcinoma; Herpes simplex virus thymidine kinase; Human sodium iodide symporter; Radiochemotherapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HERPESVIRUS VECTOR; IODINE 125; IODINE 131; LENTIVIRUS VECTOR; SODIUM IODIDE SYMPORTER; SODIUM PERCHLORATE; THYMIDINE KINASE;

ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELL STRAIN HEPG2; CELL SURVIVAL; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TRANSPORT; DRUG UPTAKE; FLUORESCENCE IMAGING; GENE; GENE EXPRESSION; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LIVER CELL CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM IODIDE SYMPORTER GENE; THYMIDINE KINASE GENE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

BIOLOGICAL TRANSPORT; GANCICLOVIR; HEP G2 CELLS; HUMANS; IODIDES; LENTIVIRUS; LIVER NEOPLASMS; SIMPLEXVIRUS; SYMPORTERS; THYMIDINE KINASE; TRANSFECTION;

EID: 79959648395     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.11.014     Document Type: Article

References (29)

1. De La Vieja A., Dohan O., Levy O., Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000, 80:1083-1105.
2. Spitzweg C., Heufelder A.E., Morris J.C. Thyroid iodine transport. Thyroid 2000, 10:321-330.
3. Dai G., Levy O., Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379:458-460.
4. Smanik P.A., Liu Q., Furminger T.L., Ryu K., Xing S., Mazzaferri E.L., et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996, 226:339-345.
5. Cengic N., Baker C.H., Schutz M., Goke B., Morris J.C., Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2005, 90:4457-4464.
6. Kakinuma H., Bergert E.R., Spitzweg C., Cheville J.C., Lieber M.M., Morris J.C. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003, 63:7840-7844.
7. Spitzweg C., O'Connor M.K., Bergert E.R., Tindall D.J., Young C.Y., Morris J.C. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000, 60:6526-6530.
8. Scholz I.V., Cengic N., Baker C.H., et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005, 12:272-280.
9. Dwyer R.M., Bergert E.R., O'connor M.K., Gendler S.J., Morris J.C. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005, 11:1483-1489.
10. Schipper M.L., Weber A., Béhé M., Göke R., Joba W., Schmidt H., et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 2003, 63:1333-1338.
11. Kang J.H., Chung J.K., Lee Y.J., Shin J.H., Jeong J.M., Lee D.S., et al. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 2004, 45:1571-1576.
12. Faivre J., Clerc J., Gérolami R., Hervé J., Longuet M., Liu B., et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in Wistar rats. Cancer Res 2004, 64:8045-8051.
13. Chen L., Altmann A., Mier W., Eskerski H., Leotta K., Guo L., et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006, 47:854-862.
14. Chen L., Altman A., Mier W., Lu H., Zhu R., Haberkorn U. 99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. Nucl Med Biol 2006, 33:575-580.
15. Carlin S., Cunningham S.H., Boyd M., McCluskey A.G., Mairs R.J. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000, 7:1529-1536.
16. Haberkorn U., Kinscherf R., Kissel M., Kübler W., Mahmut M., Sieger S., et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 2003, 10:774-780.
17. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000, 60:3989-3999.
18. Lal S., Lauer U.M., Niethammer D., Beck J.F., Schlegel P.G. Suicide gene: past, present and future perspectives. Immunol Today 2000, 21:48-54.
19. Fillat C., Carrio M., Cascante A., Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003, 3:13-26.
20. Engelmann C., Heslan J.M., Fabre M., Lagarde J.P., Klatzmann D., Panis Y. Importance, mechanisms and limitations of the distant bystander effect in cancer gene therapy of experimental liver tumors. Cancer Lett 2002, 179:59-69.
21. Agard C., Ligeza C., Dupas B., Izembart A., El Kouri C., Moullier P., et al. Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther 2001, 8:128-136.
22. Kawashita Y., Ohtsuru A., Miki F., Kuroda H., Morishita M., Kaneda Y., et al. Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy. Gene Ther 2005, 12:1633-1639.
23. Huang S.Y., Zhang D.S., Han J.Q., Zhang N., Zhang S.Z., Mu W.L., et al. Radiosensitization and anti-tumour effects of cytosine deaminase and thymidine kinase fusion suicide gene in human adenoid cystic carcinoma cells. J Int Med Res 2009, 37:479-490.
24. Rosenberg E., Hawkins W., Holmes M., Amir C., Schmidt-Ullrich R.K., Lin P.S., et al. Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int J Radiat Oncol Biol Phys 2002, 52:831-836.
25. Mandell R.B., Mandell L.Z., Link C.J. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999, 59:661-668.
26. Llovet J., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
27. Blum H.E. Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19:129-145.
28. Sangro B., Mazzolini G., Ruiz M., Ruiz J., Quiroga J., Herrero I., et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther 2010.
29. Yang L., Chiang Y., Lenz H.J., Danenberg K.D., Spears C.P., Gordon E.M., et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther 1998, 9:719-728.